A Randomized Double-blind Controlled Study of Repetitive Transcranial Magnetic Stimulation (rTMS) for the Treatment of Negative Symptoms in Schizophrenia Patients.

Shanghai Mental Health Center1 site in 1 country60 target enrollmentJuly 2016

ConditionsSchizophrenia

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Schizophrenia
Sponsor: Shanghai Mental Health Center
Enrollment: 60
Locations: 1
Primary Endpoint: Change from baseline in clinical improvement of negative symptoms (Scale for Assessment of Negative Symptoms [SANS], and Positive and Negative Syndrome Scale [PANSS] negative symptoms subscale)
Last Updated: 8 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

This study is to determine whether high frequency repetitive transcranial magnetic stimulation (rTMS) is effective in the treatment of negative symptoms in schizophrenia patients

Detailed Description

The principal objective of this trial is to investigate the effect of high frequency rTMS on negative symptoms in schizophrenia.

Registry

clinicaltrials.gov

Start Date

July 2016

End Date

December 2018

Last Updated

8 years ago

Study Type

Interventional

Study Design

Parallel

Sex

All

Investigators

Sponsor

Shanghai Mental Health Center

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•The diagnosis of schizophrenia according to DSM-IV；
•18～55 years old；
•schizophrenic illness duration longer than one year;
•The sum of negative scores in the range Positive and negative symptom score (PANSS) must be 20 points or higher, at least one item from the area of negative symptoms (N1-N7) must be ≥ 4 points (at least moderate, clinically significant symptoms), and improvement in negative symptom-sum (measuring by PANSS) must be 10% or lower during the last two weeks before rTMS stimulation.
•Have a stable and consistent drug treatment at least two weeks prior the rTMS treatment;
•Able to adhere to the treatment schedule;
•Dextromanual, normal vision and hearing;
•Signed an informed consent

Exclusion Criteria

•rTMS contraindications: intracranial metal substance, with heart pacemakers and cochlear implants, intracranial pressure;
•Acute risk of suicide and impulse；
•patients to be diagnosed according to DSM-IV for substance abused, development delayed;
•suffering from serious physical disease and can not accept the treatment;
•history of epileptic seizures or the presence of epileptic activity documented on the basis of EEG;
•difficult to maintain the current drug treatment for at least 1 month;
•undergoing ECT or MECT in last 3 months;
•current treatment with anticonvulsant acting drugs such as anticonvulsants, benzodiazepines.

Outcomes

Primary Outcomes

Change from baseline in clinical improvement of negative symptoms (Scale for Assessment of Negative Symptoms [SANS], and Positive and Negative Syndrome Scale [PANSS] negative symptoms subscale)

Time Frame: 3 times (Before treatment,immediately after treatment,4 weeks after treatment)

Secondary Outcomes

Change from baseline in Positive and Negative Syndrome Scale [PANSS] positive symptoms subscale(3 times (Before treatment,immediately after treatment,4 weeks after treatment))
Change from baseline in Calgary Depression Scale for Schizophrenia [CDSS](3 times (Before treatment,immediately after treatment,4 weeks after treatment))
Change from baseline in Clinician Rated Dimensions of Psychosis Symptom [CRDPS](3 times (Before treatment,immediately after treatment,4 weeks after treatment))
Change from baseline in WHO Disability Assessment Schedule 2.0 [WHODAS 2.0](3 times (Before treatment,immediately after treatment,4 weeks after treatment))
Change from baseline in clinical global impression [CGI](3 times (Before treatment,immediately after treatment,4 weeks after treatment))
Change from baseline in Simpson-Angus Scale [SAS](3 times (Before treatment,immediately after treatment,4 weeks after treatment))